Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$13.43 -0.5%	$13.89	$7.64 ▼ $17.75	$1.60B	1.76	2.27 million shs	2.23 million shs
BHVN Biohaven	$15.43 -1.1%	$18.24	$14.33 ▼ $55.70	$1.58B	0.95	1.26 million shs	1.36 million shs
CMPS COMPASS Pathways	$4.39 -2.9%	$3.87	$2.49 ▼ $8.54	$410.74M	2.25	894,819 shs	1.37 million shs
DYN Dyne Therapeutics	$14.41 -0.3%	$11.04	$6.36 ▼ $47.45	$1.64B	1.17	1.68 million shs	1.75 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-1.68%	-0.07%	-2.32%	-7.66%	+66.67%
BHVN Biohaven	-0.35%	-3.41%	-20.05%	-46.68%	-53.83%
CMPS COMPASS Pathways	-1.53%	-0.22%	+15.90%	+29.89%	-33.92%
DYN Dyne Therapeutics	-0.75%	+3.36%	+19.50%	+20.00%	-56.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	2.0455 of 5 stars	3.4	1.0	2.7	1.7	0.6
BHVN Biohaven	3.0042 of 5 stars	4.5	1.0	1.8	2.5	0.6
CMPS COMPASS Pathways	2.612 of 5 stars	3.5	3.0	3.3	0.8	0.6
DYN Dyne Therapeutics	2.6912 of 5 stars	4.5	0.0	2.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	39.99% Upside
BHVN Biohaven	3.07	Buy	$59.46	285.46% Upside
CMPS COMPASS Pathways	3.00	Buy	$18.83	329.01% Upside
DYN Dyne Therapeutics	3.00	Buy	$44.93	211.79% Upside

Current Analyst Ratings Breakdown

Latest CMPS, BHVN, ARQT, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	DYN Dyne Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/2/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$60.00 ➝ $34.00
5/29/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$46.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/23/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/19/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$54.00 ➝ $21.00
5/13/2025	BHVN Biohaven	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$61.00 ➝ $54.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
5/9/2025	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $38.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$212.82M	7.52	N/A	N/A	$0.94 per share	14.29
BHVN Biohaven	N/A	N/A	N/A	N/A	$5.34 per share	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$3.65 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$1.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$262.14M	-$1.04	N/A	N/A	N/A	-140.97%	-119.11%	-45.95%	8/13/2025 (Estimated)
BHVN Biohaven	-$408.17M	-$9.36	N/A	N/A	N/A	N/A	-225.12%	-158.89%	8/5/2025 (Estimated)
CMPS COMPASS Pathways	-$118.46M	-$1.99	N/A	N/A	N/A	N/A	-63.85%	-51.97%	7/30/2025 (Estimated)
DYN Dyne Therapeutics	-$235.94M	-$3.59	N/A	N/A	N/A	N/A	-57.46%	-51.62%	8/11/2025 (Estimated)

Latest CMPS, BHVN, ARQT, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.67	2.46	2.38
BHVN Biohaven	N/A	2.89	2.89
CMPS COMPASS Pathways	0.15	8.91	8.91
DYN Dyne Therapeutics	N/A	17.02	17.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
BHVN Biohaven	88.78%
CMPS COMPASS Pathways	46.19%
DYN Dyne Therapeutics	96.68%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
BHVN Biohaven	16.00%
CMPS COMPASS Pathways	3.93%
DYN Dyne Therapeutics	14.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	105.93 million	Optionable
BHVN Biohaven	239	102.11 million	84.94 million	Optionable
CMPS COMPASS Pathways	120	93.56 million	65.51 million	Optionable
DYN Dyne Therapeutics	100	113.67 million	80.63 million	Optionable

CMPS, BHVN, ARQT, and DYN Headlines

Recent News About These Companies

Dyne Therapeutics, Inc. (NASDAQ:DYN) Position Boosted by SG Americas Securities LLC

June 13 at 4:21 AM | marketbeat.com

Raymond James Begins Coverage on Dyne Therapeutics (NASDAQ:DYN)

June 13 at 2:38 AM | americanbankingnews.com

Raymond James bullish on biotech firms on favorable valuation

June 12 at 1:00 AM | in.investing.com

Dyne Therapeutics (NASDAQ:DYN) Now Covered by Raymond James

June 11 at 10:17 AM | marketbeat.com

Dyne Therapeutics officer sells shares worth $1,949

June 8, 2025 | investing.com

Millennium Management LLC Acquires 31,545 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

June 6, 2025 | marketbeat.com

US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs

June 5, 2025 | msn.com

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

June 5, 2025 | globenewswire.com

Oppenheimer Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)

June 4, 2025 | americanbankingnews.com

Dyne Therapeutics (NASDAQ:DYN) Earns Outperform Rating from Analysts at Oppenheimer

June 2, 2025 | marketbeat.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 56.1% in May

June 2, 2025 | marketbeat.com

Squarepoint Ops LLC Has $1.22 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

June 1, 2025 | marketbeat.com

Bank of America Corp DE Decreases Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

June 1, 2025 | marketbeat.com

Dyne Therapeutics (NASDAQ:DYN) Shares Down 5.5% - Should You Sell?

May 31, 2025 | marketbeat.com

Evercore ISI Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)

May 30, 2025 | marketbeat.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by Brokerages

May 30, 2025 | marketbeat.com

Voloridge Investment Management LLC Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

May 29, 2025 | marketbeat.com

Deutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

May 26, 2025 | marketbeat.com

Woodline Partners LP Sells 403,483 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

May 24, 2025 | marketbeat.com

Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by D. E. Shaw & Co. Inc.

May 21, 2025 | marketbeat.com

66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial Markets

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, BHVN, ARQT, and DYN Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$13.43 -0.07 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$13.52 +0.09 (+0.63%)

As of 06:12 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Biohaven NYSE:BHVN

$15.43 -0.16 (-1.05%)

Closing price 03:59 PM Eastern

Extended Trading

$15.45 +0.02 (+0.16%)

As of 05:15 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

COMPASS Pathways NASDAQ:CMPS

$4.39 -0.13 (-2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$4.36 -0.02 (-0.57%)

As of 06:06 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Dyne Therapeutics NASDAQ:DYN

$14.41 -0.05 (-0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$14.40 -0.01 (-0.03%)

As of 04:23 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time